# TROP2 CAREngineered Cord Blood-Derived NK Cells + Belzutifan In Pancreatic Cancer

Source: https://onco.cc/trials/nct07377526/  
OnCo record `nct07377526` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

This study tests TROP-2-directed treatment; the registry reports that it is suspended.

## Summary

The registry lists NCT07377526 as suspended, last updated 2026-07-31. Enrolment is 37 planned participants, an estimate. Interventions: TGFBR2 KO CAR27/IL-15 NK cells. Primary measures include Safety and Adverse Events (AEs). The registry reason for stopping is: PI Request No results are posted in the registry; this does not exclude separate publications. The title and brief summary specify intraperitoneal cells with oral belzutifan, but the intervention table incorrectly describes the cells as given by mouth; the route is not reproduced as a dosing recommendation.

## Fields

- Kind: Trial
- Last checked: 2026-10-06
- Registry id: NCT07377526
- Phase: 1/2
- Setting: Phase 1/2 Study Of IL15-Transduced, TGFBR2 KO, TROP2 CAR- Engineered Cord Blood-Derived NK Cells Administered Intraperitoneally And Intravenously In Combination With Oral Belzutifan For The Management Of Pancreatic Cancer
- Sponsor: M.D. Anderson Cancer Center

## Sources

- ClinicalTrials.gov NCT07377526: https://clinicaltrials.gov/study/NCT07377526

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- targets: [TROP2](https://onco.cc/targets/trop2/)

---
JSON: https://onco.cc/api/v1/entities/nct07377526.json